Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and ...

Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution ...

Cipla received approval from India's Central Drugs Standard Control Organisation to distribute and market Afrezza inhalation ...

Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

Cipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, ...